Research progress of influenza vaccination, pneumococcal vaccination and COVID-19 vaccination among cancer patients.
10.3760/cma.j.cn112150-20220413-00353
- Author:
Hai Tian SUI
1
;
Yu GUO
1
;
Zhong Nan YANG
1
;
Jin Feng SU
1
;
Xiang SHU
1
;
Yang ZHANG
1
;
Xiao Ming YANG
2
Author Information
1. China National Biotec Group, Beijing 100029, China.
2. China National Biotec Group, Beijing 100029, China National United Vaccine Engineering Technology Research Center, Wuhan 430207, China.
- Publication Type:Journal Article
- MeSH:
Humans;
Influenza, Human/prevention & control*;
COVID-19 Vaccines;
COVID-19/prevention & control*;
Influenza Vaccines/therapeutic use*;
Vaccination;
Pneumococcal Vaccines/therapeutic use*;
Streptococcus pneumoniae;
Neoplasms
- From:
Chinese Journal of Preventive Medicine
2023;57(1):100-106
- CountryChina
- Language:Chinese
-
Abstract:
This article reviews the relevant studies on the efficacy and safety of influenza, pneumococcal and COVID-19 vaccination among tumor patients worldwide in recent years. By combing and analyzing the retrieved literature, the results show that influenza and pneumococcal vaccination can significantly reduce the morbidity and hospitalization rate of infectious diseases in tumor patients, reduce the risk of cardiovascular events and death, and significantly improve survival prognosis. COVID-19 vaccination can also protect tumor patients, especially those who have completed full dose vaccination. Authoritative guidelines and consensuses worldwide all recommend that tumor patients receive influenza, pneumococcal and COVID-19 vaccines. We should carry out relevant researches, as well as take effective measures to strengthen patient education, so that tumor patients can fully experience the health protection brought by the vaccine to this specific group.
